^
    Back
    Association details:
    Biomarker:ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor) +
    Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report

    Published date:
    03/23/2022
    Excerpt:
    We report a case of a 27-year-old female nonsmoker diagnosed with ALK-rearranged metastatic lung adenocarcinoma. She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations. Germline BRCA2 p.F2801fs was also identified….Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response.
    DOI:
    10.1097/CAD.0000000000001303